Dr Ferdy van Geest, (Erasmus Medical Center, Rotterdam, The Netherlands) kindly spoke with us about the results of his study investigating Triac in patients with MCT8.
The abstract entitled ‘Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study’ (Abstract 82) was given at European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September.
Questions
1. What clinical characteristics do patients with monocarboxylate transporter MCT8 deficiency display? (0:35)
2. Please describe the mechanism of action of Triac and what has been previously established regarding efficacy and safety in patients with MCT8 deficiency? (2:19)
3. What further evidence did this real-life cohort study aim to gather? (4:02)
4. What were the key results of the study? (6:06)
5. How will Triac impact the treatment of patients with MCT8 deficiency? (7:06)
Disclosures: The Erasmus Medical Center (Rotterdam, Netherlands), which employs FSvG, receives royalties from Rare Thyroid Therapeutics (the manufacturer of Triac), dependent on commercialization. None of the authors will benefit personally from any royalties. Rare Thyroid Therapeutics had no influence on the conduct or analysis of this study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September 2021.
van Geest F, Groeneweg S, van Toor H, et al. 82: Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study. Eur Thyroid J 2021;10(Suppl. 1):6.
